{
    "root": "2ebf334e-6f66-4ef7-b0ca-9d21ccb3165e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Lurasidone Hydrochloride"
    },
    "value": "20250224",
    "ingredients": [
        {
            "name": "LURASIDONE HYDROCHLORIDE",
            "code": "O0P4I5851I"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "ALGINIC ACID",
            "code": "8C3Z4148WZ"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "indications": "lurasidone hydrochloride tablet indicated : treatment adult adolescent patients ( 13 17 years ) schizophrenia [ ( 14.1 ) ] . monotherapy treatment adult pediatric patients ( 10 17 years ) major depressive episode associated bipolar disorder ( bipolar depression ) [ ( 14.2 ) ] . adjunctive treatment lithium valproate adult patients major depressive episode associated bipolar disorder ( bipolar depression ) [ ( 14.2 ) ] .",
    "contraindications": "lurasidone hydrochloride tablets taken food ( least 350 calories ) . food substantially increases absorption lurasidone hydrochloride tablets ( 2.3 , 12.3 ) . indication starting dose recommended dose schizophrenia \u2013 adults ( 2.1 ) 40 mg per day 40 mg 160 mg per day schizophrenia \u2013 adolescents ( 13 17 years ) ( 2.1 ) 40 mg per day 40 mg 80 mg per day bipolar depression \u2013 adults ( 2.2 ) 20 mg per day 20 mg 120 mg per day bipolar depression \u2013 pediatric patients ( 10 17 years ) ( 2.2 ) 20 mg per day 20 mg 80 mg per day moderate severe renal impairment : recommended starting dose 20 mg per day , maximum recommended dose 80 mg per day ( 2.4 , 8.6 ) . moderate severe hepatic impairment : recommended starting dose 20 mg per day . maximum recommended dose 80 mg per day moderate hepatic impairment 40 mg per day severe hepatic impairment ( 2.5 , 8.7 ) . concomitant moderate cyp3a4 inhibitor ( e.g . , diltiazem ) : lurasidone hydrochloride tablets dose reduced half original dose level . recommended starting dose 20 mg per day . maximum recommended dose 80 mg per day ( 2.6 , 7.1 ) . concomitant moderate cyp3a4 inducer : may necessary increase dose lurasidone hydrochloride tablets ( 2.6 , 7.1 ) .",
    "warningsAndPrecautions": "lurasidone hydrochloride tablets available follows : 20 mg : white off-white , round , film-coated tablet , debossed '578 ' one side plain side . bottles 30 child resistant cap\u2026\u2026\u2026\u2026\u2026\u2026\u2026 . . ndc 47335-578-83 bottles 90 child resistant cap\u2026\u2026\u2026\u2026\u2026\u2026 . . \u2026ndc 47335-578-81 bottles 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 . \u2026\u2026ndc 47335-578-13 40 mg : white off-white , round , film-coated tablet , debossed '684 ' one side plain side . bottles 30 child resistant cap\u2026\u2026\u2026\u2026\u2026\u2026\u2026 . . ndc 47335-684-83 bottles 90 child resistant cap\u2026\u2026\u2026\u2026\u2026\u2026 . . \u2026ndc 47335-684-81 bottles 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 . \u2026\u2026ndc 47335-684-13 60 mg : white off-white , modified capsule shaped , film-coated tablet , debossed '639 ' one side plain side . bottles 30 child resistant cap\u2026\u2026\u2026\u2026\u2026\u2026\u2026 . . ndc 47335-639-83 bottles 90 child resistant cap\u2026\u2026\u2026\u2026\u2026\u2026 . . \u2026ndc 47335-639-81 bottles 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 . \u2026\u2026ndc 47335-639-13 80 mg : pale green colored , oval shaped , film-coated tablet , debossed '685 ' one side plain side . bottles 30 child resistant cap\u2026\u2026\u2026\u2026\u2026\u2026\u2026 . . ndc 47335-685-83 bottles 90 child resistant cap\u2026\u2026\u2026\u2026\u2026\u2026 . . \u2026ndc 47335-685-81 bottles 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 . \u2026\u2026ndc 47335-685-13 120 mg : white off-white , oval shaped , film-coated tablet , debossed '579 ' one side plain side . bottles 30 child resistant cap\u2026\u2026\u2026\u2026\u2026\u2026\u2026 . . ndc 47335-579-83 bottles 90 child resistant cap\u2026\u2026\u2026\u2026\u2026\u2026 . . \u2026ndc 47335-579-81 bottles 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 . \u2026\u2026ndc 47335-579-13 storage store lurasidone hydrochloride tablets 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "known hypersensitivity lurasidone hydrochloride components formulation . angioedema observed lurasidone [ ( 6.1 ) ] . strong cyp3a4 inhibitors ( e.g . , ketoconazole , clarithromycin , ritonavir , voriconazole , mibefradil , etc . ) [ ( 7.1 ) ] . strong cyp3a4 inducers ( e.g . , rifampin , avasimibe , st. john \u2019 wort , phenytoin , carbamazepine , etc . ) [ ( 7.1 ) ] .",
    "indications_original": "Lurasidone hydrochloride tablet is indicated for:\n                  \n                     Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies (14.1)].\n                     \n                     Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)].\n                     \n                     Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)].",
    "contraindications_original": "Lurasidone hydrochloride tablets should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of lurasidone hydrochloride tablets (2.3, 12.3). Indication Starting Dose Recommended Dose Schizophrenia \u2013 adults (2.1) 40 mg per day 40 mg to 160 mg per day Schizophrenia \u2013 adolescents (13 to 17 years) (2.1) 40 mg per day 40 mg to 80 mg per day Bipolar Depression \u2013 adults (2.2) 20 mg per day 20 mg to 120 mg per day Bipolar Depression \u2013 pediatric patients (10 to 17 years) (2.2) 20 mg per day 20 mg to 80 mg per day Moderate and Severe Renal Impairment: Recommended starting dose is 20 mg per day, and the maximum recommended dose is 80 mg per day (2.4, 8.6). Moderate and Severe Hepatic Impairment: Recommended starting dose is 20 mg per day. The maximum recommended dose is 80 mg per day in moderate hepatic impairment and 40 mg per day in severe hepatic impairment (2.5, 8.7). Concomitant Use of a Moderate CYP3A4 inhibitor (e.g., diltiazem): Lurasidone hydrochloride tablets dose should be reduced to half of the original dose level. Recommended starting dose is 20 mg per day. Maximum recommended dose is 80 mg per day (2.6, 7.1). Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of lurasidone hydrochloride tablets (2.6, 7.1).",
    "warningsAndPrecautions_original": "Lurasidone hydrochloride tablets are available as follows:\u00a0 \n                  \n                     20 mg: White to off-white, round, film-coated tablet, debossed with '578' on one side and plain on other side.\n                  Bottles of 30 with Child Resistant Cap\u2026\u2026\u2026\u2026\u2026\u2026\u2026..NDC 47335-578-83\n                  Bottles of 90 with Child Resistant Cap\u2026\u2026\u2026\u2026\u2026\u2026..\u2026NDC 47335-578-81\n                  Bottles of 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026NDC 47335-578-13\n                  \n                  \n                     40 mg: White to off-white, round, film-coated tablet, debossed with '684' on one side and plain on other side.\n                  Bottles of 30 with Child Resistant Cap\u2026\u2026\u2026\u2026\u2026\u2026\u2026..NDC 47335-684-83\n                  Bottles of 90 with Child Resistant Cap\u2026\u2026\u2026\u2026\u2026\u2026..\u2026NDC 47335-684-81\n                  Bottles of 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026NDC 47335-684-13\n                  \n                  \n                     60 mg: White to off-white, modified capsule shaped, film-coated tablet, debossed with '639' on one side and plain on other side.\n                  Bottles of 30 with Child Resistant Cap\u2026\u2026\u2026\u2026\u2026\u2026\u2026..NDC 47335-639-83\n                  Bottles of 90 with Child Resistant Cap\u2026\u2026\u2026\u2026\u2026\u2026..\u2026NDC 47335-639-81\n                  Bottles of 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026NDC 47335-639-13\n                  \n                  \n                     80 mg: Pale green colored, oval shaped, film-coated tablet, debossed with '685' on one side and plain on other side.\n                  Bottles of 30 with Child Resistant Cap\u2026\u2026\u2026\u2026\u2026\u2026\u2026..NDC 47335-685-83\n                  Bottles of 90 with Child Resistant Cap\u2026\u2026\u2026\u2026\u2026\u2026..\u2026NDC 47335-685-81\n                  Bottles of 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026NDC 47335-685-13\n                  \n                  \n                     120 mg: White to off-white, oval shaped, film-coated tablet, debossed with '579' on one side and plain on other side.\n                  Bottles of 30 with Child Resistant Cap\u2026\u2026\u2026\u2026\u2026\u2026\u2026..NDC 47335-579-83\n                  Bottles of 90 with Child Resistant Cap\u2026\u2026\u2026\u2026\u2026\u2026..\u2026NDC 47335-579-81\n                  Bottles of 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026NDC 47335-579-13\n                        \u00a0\n                     \n                  \n                  \n                     \u00a0\n                  \n                  \n                     \n                        Storage\n                     \n                  \n                  Store lurasidone hydrochloride tablets at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Known\u00a0 hypersensitivity\u00a0 to\u00a0 lurasidone\u00a0 hydrochloride or\u00a0 any\u00a0 components\u00a0 in\u00a0 the\u00a0 formulation. Angioedema has been observed with lurasidone [see Adverse Reactions (6.1)].\n                     Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Drug Interactions (7.1)].\n                     \n                     Strong CYP3A4 \u00a0inducers\u00a0 (e.g.,\u00a0 rifampin,\u00a0 avasimibe,\u00a0 St.\u00a0 John\u2019s wort, phenytoin, carbamazepine, etc.) [see Drug Interactions (7.1)]."
}